TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31415063

Group type: COMPARATOR
Intervention: Control group (facility-based lymphedema care with no home-based exercise or weight loss intervention)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (strength/resistance training twice per week and 180 minutes of walking per week)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (20 weeks of meal replacements and 52 weeks of lifestyle modification counseling)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Combined exercise and weight loss intervention
Number of subjects: 351
Study: 28406774

Group type: EXPERIMENTAL
Intervention: Ligation of the thoracic duct
Number of subjects: 60

Group type: COMPARATOR
Intervention: No ligation of the thoracic duct
Number of subjects: 60
Study: 25759413

Group type: EXPERIMENTAL
Intervention: Fish skin acellular dermal matrix (ADM)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Porcine small-intestine submucosa extracellular matrix
Number of subjects: 81
Study: 23739758

Group type: EXPERIMENTAL
Intervention: Osteopathic manual treatment (OMT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham OMT
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ultrasound therapy (UST)
Number of subjects: 34
Study: 21276962

Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait-list group (treatment-as-usual, TAU)
Number of subjects: 36
Study: 18759522

Group type: EXPERIMENTAL
Intervention: Dalteparin (100 IU/kg subcutaneously twice a day for 10 days, then 100 IU/kg once a day for another 10 days)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aspirin (100 mg daily throughout the study)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 47
Study: 15921853

Group type: EXPERIMENTAL
Intervention: Resting regional cerebral blood flow (rCBF) in left amygdala, lentiform nucleus, and parahippocampal gyrus
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resting regional cerebral blood flow (rCBF) in right rostral and subgenual anterior cingulate cortices, insula and claustrum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resting regional cerebral blood flow (rCBF) in right antero‐lateral orbitofrontal cortex
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resting regional cerebral blood flow (rCBF) in right postero‐medial orbitofrontal cortex and left lentiform nucleus
Number of subjects: 15
Study: 12374537

Group type: EXPERIMENTAL
Intervention: Daily application of a standard sun protection factor 15+ broad-spectrum retail sunscreen to the head and neck, arms, and hands.
Number of subjects: 0
Study: 10424402

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 151
Study: 7493297

Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IFN-beta (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both IFN types
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IFN-alpha (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IFN-beta
Number of subjects: 40
Study: 2268495

Group type: EXPERIMENTAL
Intervention: Guided design (written simulations and small group interaction)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 50
Study: 499311

Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI) 75 mg daily for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa 750 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant drugs
Number of subjects: 0
Study: 31022754

Group type: EXPERIMENTAL
Intervention: Plasma sodium concentration ≤136 mmol/L
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plasma sodium concentration on admission
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plasma AVP on admission
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Plasma sodium concentration as a diagnostic marker
Number of subjects: 80
Study: 29460813

Group type: EXPERIMENTAL
Intervention: 1000 μg vitamin B12 daily for 8 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo supplement for 8 weeks
Number of subjects: 95
Study: 26790758

Group type: EXPERIMENTAL
Intervention: LPS administration (0.4–0.8 ng/kg body weight)
Number of subjects: 186
Study: 25330848

Group type: EXPERIMENTAL
Intervention: 20-week exercise and diet guidance intervention
Number of subjects: 38
Study: 23081705

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20642382

Group type: EXPERIMENTAL
Intervention: drospirenone + ethinylestradiol + oral L-arginine (4 g × 2/daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: drospirenone + ethinylestradiol + placebo
Number of subjects: 28
Study: 18045691

Group type: EXPERIMENTAL
Intervention: Higher intensity individualized treadmill training (HI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower intensity generalized training (LG)
Number of subjects: 30
Study: 16163916

Group type: EXPERIMENTAL
Intervention: Lateral neck X-ray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mallampati Class test
Number of subjects: 100
Study: 14579087

Group type: COMPARATOR
Intervention: Gradient histogram in the parieto-temporal lobes
Number of subjects: 87

Group type: COMPARATOR
Intervention: Count density/voxel histogram (frontal and occipital lobes) and mean gradient (frontal, temporal and parietal lobes)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Count density/voxel histogram in the frontal, parietal and occipital lobes
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Concatenated joint feature
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5D co-occurrence matrices
Number of subjects: 87
Study: 11038091

Group type: EXPERIMENTAL
Intervention: French osteotomy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dome osteotomy
Number of subjects: 25
Study: 9093710

Group type: EXPERIMENTAL
Intervention: Vinblastine + interferon-alpha (IFN-alpha-2a)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vinblastine alone
Number of subjects: 30
Study: 8444226

Group type: EXPERIMENTAL
Intervention: 5 ml/kg of 20% albumin infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5 ml/kg of maintenance fluids (placebo)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (albumin and placebo)
Number of subjects: 30
Study: 3942669

Group type: EXPERIMENTAL
Intervention: 10 ml of water with diazepam tablets (group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 50 ml of water with diazepam tablets (group B)
Number of subjects: 33
Study: 29610265

Group type: EXPERIMENTAL
Intervention: Preconception blood pressure (systolic: 111.6 mm Hg, diastolic: 72.5 mm Hg)
Number of subjects: 1228

Group type: EXPERIMENTAL
Intervention: Preconception blood pressure
Number of subjects: 1228
Study: 27354129

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (1000 mg orally twice daily during and for 4 weeks after RT)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (orally twice daily during and for 4 weeks after RT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 24397244

Group type: EXPERIMENTAL
Intervention: Double balloon catheter with EASI
Number of subjects: 186

Group type: COMPARATOR
Intervention: Single balloon catheter with EASI
Number of subjects: 186
Study: 22540161

Group type: EXPERIMENTAL
Intervention: 35 IU kg(‐1) rhFVIII
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 70 IU kg(‐1) rhFVIII
Number of subjects: 12

Group type: COMPARATOR
Intervention: TB-402
Number of subjects: 12
Study: 20080466

Group type: EXPERIMENTAL
Intervention: VEGF-targeting drugs (bevacizumab, sunitinib, sorafenib, axitinib, pazopanib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PI3K‐mTOR inhibitors (temsirolimus, everolimus)
Number of subjects: 0
Study: 18396444

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Parapharyngeal invasion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cavernous sinus invasion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Tumor vascular invasion
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Parapharyngeal and cavernous sinus invasion
Number of subjects: 57
Study: 15812585

Group type: EXPERIMENTAL
Intervention: Gonyautoxin infiltration (100 units in 1 ml)
Number of subjects: 50
Study: 12413670

Group type: EXPERIMENTAL
Intervention: Proteolytic enzymes (papain, trypsin, chymotrypsin)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 10797108

Group type: EXPERIMENTAL
Intervention: 18.5% glucose polymer
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 18.5% sucrose
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 12% sucrose
Number of subjects: 7
Study: 8882257

Group type: EXPERIMENTAL
Intervention: Aspiration of 2 ml of patient's blood into propofol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lignocaine 20 mg added to propofol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline 2 ml added to propofol
Number of subjects: 100
Study: 1467072

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study: 3918653

Group type: EXPERIMENTAL
Intervention: 16.64 mg glyceryl trinitrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg isosorbide dinitrate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31096027

Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS) prediction
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Nomogram for breast cancer-specific survival (BCSS) prediction
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Nomogram predictions for OS and BCSS
Number of subjects: 789
Study: 29808262

Group type: EXPERIMENTAL
Intervention: 25 ml of 0.25% levobupivacaine + 1 ml (20 mg) nalbuphine
Number of subjects: 135

Group type: COMPARATOR
Intervention: 25 ml of 0.5% levobupivacaine + 1 ml normal saline
Number of subjects: 135

Group type: COMPARATOR
Intervention: 25 ml of 0.25% levobupivacaine + 1 ml normal saline
Number of subjects: 135
Study: 26939572

Group type: EXPERIMENTAL
Intervention: GSK672 90 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GSK672 10-90 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: GSK672
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 90
Study: 23819250

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment and routine western medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 60
Study: 21838089

Group type: EXPERIMENTAL
Intervention: Micronized tretinoin gel 0.05%
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.1%
Number of subjects: 483

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 483
Study: 19480872

Group type: EXPERIMENTAL
Intervention: Hippotherapy (10 minutes)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Barrel-sitting (10 minutes)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hippotherapy (12 weekly sessions)
Number of subjects: 53
Study: 16500773

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Kundalini yoga
Number of subjects: 33
Study: 14711911

Group type: EXPERIMENTAL
Intervention: Interferon gamma‐1b
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 11717598

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9205393

Group type: EXPERIMENTAL
Intervention: New therapeutic bed
Number of subjects: 256
Study: 8181020

Group type: EXPERIMENTAL
Intervention: Therapeutic modalities for managing ventricular arrhythmias in CHF
Number of subjects: 0
Study: 3584746

Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31496270

Group type: EXPERIMENTAL
Intervention: Early numeracy Tier 2 intervention delivered four days per week for 20 weeks.
Number of subjects: 121

Group type: COMPARATOR
Intervention: Comparison condition (control group).
Number of subjects: 121
Study: 30467977

Group type: EXPERIMENTAL
Intervention: Fecal samples
Number of subjects: 31

Group type: COMPARATOR
Intervention: Colonic biopsies
Number of subjects: 31
Study: 27016618

Group type: EXPERIMENTAL
Intervention: 10 mg/kg IV-TXA
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 15 mg/kg IV-TXA
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 124
Study: 24193993

Group type: EXPERIMENTAL
Intervention: 100 or 200 mg of lidocaine injections
Number of subjects: 62

Group type: COMPARATOR
Intervention: saline injections
Number of subjects: 62
Study: 23535609

Group type: EXPERIMENTAL
Intervention: Prenatal lipid-based nutrient supplements (LNSs)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Multiple micronutrient tablets
Number of subjects: 197
Study: 20955281

Group type: EXPERIMENTAL
Intervention: Updated comorbidity assessments
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Baseline comorbidity assessments
Number of subjects: 1846
Study: 18219348

Group type: EXPERIMENTAL
Intervention: Dalteparin subcutaneously every day for 20 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) daily for 20 days
Number of subjects: 0
Study: 21033082

Group type: EXPERIMENTAL
Intervention: Taurine treatment for NAFLD
Number of subjects: 0
Study: 16282543

Group type: EXPERIMENTAL
Intervention: PCK1‐232G/G genotype
Number of subjects: 150

Group type: COMPARATOR
Intervention: Other genotypes
Number of subjects: 150
Study: 12048150

Group type: EXPERIMENTAL
Intervention: Stereotype suppression instructions in experiment 1
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Stereotype suppression instructions in experiment 2
Number of subjects: 110

Group type: COMPARATOR
Intervention: Previous contact with persons with mental illness
Number of subjects: 110
Study: 9721990

Group type: EXPERIMENTAL
Intervention: Videomanometry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy age‐matched controls
Number of subjects: 0
Study: 7990065

Group type: EXPERIMENTAL
Intervention: Hypnosis sessions (3 sessions)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Non-hypnotic sessions (3 sessions)
Number of subjects: 5
Study: 3178924

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (both doses)
Number of subjects: 0
Study: 12380852

Group type: EXPERIMENTAL
Intervention: Mailed personalized normative feedback (PNF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attention-control (C)
Number of subjects: 100
Study: 30081012

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 26980216

Group type: EXPERIMENTAL
Intervention: Percutaneous para‐aneurysmal saline injection
Number of subjects: 51
Study: 24140072

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 134
Study: 22337474

Group type: EXPERIMENTAL
Intervention: Dead Sea salt (DSS) irrigations and DSS nasal spray
Number of subjects: 114

Group type: COMPARATOR
Intervention: Fluticasone spray and hypertonic saline irrigation and spray
Number of subjects: 114
Study: 20176716

Group type: EXPERIMENTAL
Intervention: Impedance cardiography for AV interval optimization
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Impedance cardiography for VV interval optimization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Echocardiographic methods for AV/VV interval optimization
Number of subjects: 20
Study: 18419328

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (11 mL)
Number of subjects: 140

Group type: COMPARATOR
Intervention: 40% DMSO with lidocaine (10 mL)
Number of subjects: 140
Study: 15756405

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 20
Study: 12463727

Group type: EXPERIMENTAL
Intervention: Roxifiban (XV459) 0.5 to 1.25 mg daily for 7 to 10 days
Number of subjects: 41
Study: 10348512

Group type: EXPERIMENTAL
Intervention: mylohyoid nerve block + IAN block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine + 3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: mock mylohyoid nerve block + IAN block (3.6 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: mylohyoid nerve block + mock IAN block (1.8 mL of 2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 30
Study: 8622107

Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg once daily
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Isepamicin 7.5 mg/kg twice daily
Number of subjects: 130

Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 130
Study: 2188770

Group type: EXPERIMENTAL
Intervention: Epoetin beta (10, 50, 150, and 500 IU/kg) administered intravenously
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epoetin beta (1000 IU/kg) administered intravenously in an open manner
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epoetin beta (various doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6994369

Group type: EXPERIMENTAL
Intervention: Iso‐Ameritrat (2.5 mg Isosorbide Dinitrate and 10 mg Pentaerythritol Tetranitrate and 200 mg Meprobamate)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ameritrat (10 mg Pentaerythritol Tetranitrate and 200 mg Meprobamate)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Meprobamate (200 mg)
Number of subjects: 9
Study: 31268377

Group type: EXPERIMENTAL
Intervention: Traumatic Perception of Birth Psychoeducation Program (TPBPP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 30258854

Group type: EXPERIMENTAL
Intervention: Higher percentage of daily energy intake from fats
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Higher percent of energy intake from proteins
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Higher percent of energy intake from carbohydrates
Number of subjects: 257
Study: 27495373

Group type: EXPERIMENTAL
Intervention: Mail survey mode
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Telephone survey mode
Number of subjects: 2839

Group type: EXPERIMENTAL
Intervention: Caregivers with lower educational attainment
Number of subjects: 2839

Group type: COMPARATOR
Intervention: Caregivers with higher educational attainment
Number of subjects: 2839
Study: 24374821

Group type: EXPERIMENTAL
Intervention: BMS‐986001 (10, 30, 100, 300, 600, and 900 mg fed; 100 and 300 mg fasted)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22083536

Group type: EXPERIMENTAL
Intervention: Maximal arm exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Maximal leg exercise
Number of subjects: 15
Study: 19768533

Group type: EXPERIMENTAL
Intervention: Concomitant docetaxel (75 mg/m2 on day 8) plus gemcitabine (1,000 mg/m2 on days 1 + 8) for 8 cycles
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sequential docetaxel (100 mg/m2 on day 1 for 4 cycles) followed by gemcitabine (1,250 mg/m2 on days 1 + 8 for 4 cycles)
Number of subjects: 100
Study: 17689809

Group type: EXPERIMENTAL
Intervention: Probabilistic threshold technique (TT) for measuring maximum acceptable risk increments (MARI) for adverse effects from OA medication.
Number of subjects: 196
Study: 16344838

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (MAS XR) 10-60 mg/day (mean dose: 37.2 mg/day)
Number of subjects: 725
Study: 12131384

Group type: EXPERIMENTAL
Intervention: Turning Point: Rethinking Violence (TPRV) program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard court sentencing options (100 hours of community service)
Number of subjects: 38
Study: 11488519

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 over 1 hour
Number of subjects: 18

Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m2 over 3 hours
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of paclitaxel and carboplatin
Number of subjects: 18
Study: 10085709

Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Duration of hemodialysis treatment
Number of subjects: 24
Study: 7759968

Group type: EXPERIMENTAL
Intervention: ZIFT
Number of subjects: 60

Group type: COMPARATOR
Intervention: IVF-ET
Number of subjects: 60
Study: 3190220

Group type: EXPERIMENTAL
Intervention: BDD supplemented with aspartame
Number of subjects: 59

Group type: COMPARATOR
Intervention: Balanced Deficit Diet (BDD)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 59
Study: 1098727

Group type: EXPERIMENTAL
Intervention: Levamisole 50 mg three times a day by mouth for three days every fortnight, starting three days before surgery
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 111

Group type: COMPARATOR
Intervention: Levamisole and Placebo
Number of subjects: 111
Study: 31689125

Group type: EXPERIMENTAL
Intervention: Nonwhite population
Number of subjects: 302

Group type: COMPARATOR
Intervention: White population
Number of subjects: 302
Study: 30959470

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control arm (symptom management education)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 460
Study: 28629132

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (2800 IU daily for eight weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200